Nov 12, 2021
Applied Therapeutics Reports Third Quarter 2021 Financial Results
Data from pilot trial of AT-007 in SORD deficiency expresses substantial and significant reduction in sorbitol Data from the ACTION-Galactosemia Kids study demonstrates statistically significant reduction in plasma galactitol NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc.
Aug 12, 2021
Applied Therapeutics Reports Second Quarter 2021 Financial Results
NDA submission for AT-007 in Galactosemia expected in Q3 2021; commercial preparations ongoing Ended Q2 2021 with a strong balance sheet with $125.6 million in cash and cash equivalents and short-term investments NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc.
Jun 28, 2021
Applied Therapeutics Added to Russell Microcap® Index
NEW YORK, June 28, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the Company has joined
Jun 25, 2021
Applied Therapeutics Announces Presentation of Data on the Prevalence of Diabetic Cardiomyopathy at the 81st Scientific Sessions of the 2021 Annual Meeting of the American Diabetes Association
~1 in 5 people with diabetes or pre-diabetes have Diabetic Cardiomyopathy, a serious and progressive disease that limits the heart’s ability to function   People with diabetes or pre-diabetes who have Diabetic Cardiomyopathy are at high risk for developing overt heart failure NEW YORK, June 25,
Displaying 1 - 10 of 21


Print Page
Print Page
Email Alerts
RSS Feeds
RSS Feeds
Contact IR
Contact IR
AP_logo_KO
linkedin
facebook
twitter

©2021 Applied Therapeutics All Rights Reserved

linkedin
facebook
twitter
AP_logo_KO

©2021 Applied Therapeutics All Rights Reserved